NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zealand Pharma A/S (PINK: ZLDPF)

 
ZLDPF Technical Analysis
1
As on 26th Jul 2024 ZLDPF STOCK Price closed @ 129.24 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ZLDPFSTOCK Price

Open 132.56 Change Price %
High 133.08 1 Day N/A N/A
Low 129.00 1 Week 0.00 0.00
Close 129.24 1 Month 0.00 0.00
Volume 4086 1 Year 0.00 0.00
52 Week High 0.00 | 52 Week Low 0.00
 
PINK USA Most Active Stocks
TXGE 2360.83 %
AABB 0.03 %
HYSR 0.02 %
WRFX 0.01 %
AMXVF 1.05 10.53%
HTZZ 24.68 1.52%
SPZI 0.01 %
CRGE 0.02 -33.33%
POFCY 0.12 %
CRHCF 61.23 0.16%
 
PINK USA Top Gainers Stocks
ANAV 12.05 30025.00%
BKGM 950.00 6566.67%
NZERD 0.36 800.00%
MMCWF 0.07 600.00%
TDCH 0.60 275.00%
ACFL 0.02 100.00%
KRBF 1.10 80.33%
BLFDF 0.07 75.00%
RDBBY 4.48 63.50%
CLNH 6.40 56.10%
 
PINK USA Top Losers Stocks
SKLV 0.06 -100.00%
SKLV 0.06 -100.00%
FFVWF 0.01 -94.12%
PTHIF 0.10 -90.91%
PTHIF 0.10 -90.91%
GFDV 0.01 -88.89%
MINRF 0.05 -82.14%
KIRY 0.02 -80.00%
ATMS 0.50 -73.54%
GMSQF 0.03 -72.73%
 
 
ZLDPF
Daily Charts
ZLDPF
Intraday Charts
Whats New @
Bazaartrend
ZLDPF
Free Analysis
 
ZLDPF Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
SUPPORT0.00
 
ZLDPF Forecast July 2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
ZLDPF Weekly Forecast
4th UP Forecast0.00
3rd UP Forecast0.00
2nd UP Forecast0.00
1st UP Forecast0.00
1st DOWN Forecast0.00
2nd DOWN Forecast0.00
3rd DOWN Forecast0.00
4th DOWN Forecast0.00
 
ZLDPF Forecast2024
4th UP Forecast0
3rd UP Forecast0
2nd UP Forecast0
1st UP Forecast0
1st DOWN Forecast0
2nd DOWN Forecast0
3rd DOWN Forecast0
4th DOWN Forecast0
 
 
ZLDPF Other Details
Segment EQ
Market Capital 1372448384.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ZLDPF Address
ZLDPF
 
ZLDPF Latest News
 
Your Comments and Response on Zealand Pharma A/S
 
ZLDPF Business Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Address: Sydmarken 11, Copenhagen, Denmark, 2860
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service